Low dose mitomycin-C in severe vernal keratoconjunctivitis: a randomized prospective double blind study.
OBJECTIVE
To study the efficacy and safety of low dose topical Mitomycin C (MMC) in severe Vernal keratoconjunctivitis (VKC).


METHODS
Placebo controlled double masked randomized clinical trial.


METHODS
Twenty-eight patients with severe VKC were randomly assigned to receive either topical MMC (0.01%) (n=17) or distilled water (n=11) three times daily for a period of two weeks. Signs and symptoms were recorded on day of presentation and at the end of treatment period (2 weeks). Mann Whitney test was used to analyze the signs and symptoms in the two groups.


RESULTS
No statistically significant difference was observed in terms of severity of symptoms at presentation. At two weeks patients in the MMC group showed significant decrease in tearing, foreign body sensation, discharge, hyperemia, punctate keratitis, limbal edema and trantas spots. No adverse effect of MMC was observed.


CONCLUSIONS
Short term low dose topical MMC is an effective and safe drug to control acute exacerbations in patients of severe VKC refractory to conventional treatment.
Jain
Arun K
AK
Department of Ophthalmology, Post Graduate institute of Medical Education and Research, (PGIMER), Chandigarh, India. arooonjain@hotmail.com
Sukhija
Jaspreet
J
D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D002648:Child; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage*; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D009883:Ophthalmic Solutions; D016685:Mitomycin